Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections

Keyphrases

• Acute Bacterial Skin 40%
• Alternative Antibiotics 10%
• Antibiotic Choices 10%
• Antibiotics 20%
• Area Cover 10%
• Clinical Efficacy 10%
• Clinical Safety 10%
• Coagulase-negative Staphylococci (CoNS) 10%
• Drug Evaluation 100%
• Expert Opinion 10%
• Financial Cost 10%
• Gram-positive Pathogens 10%
• Intravenous Formulation 10%
• Linezolid 40%
• Long Half-life 10%
• Methicillin-resistant Staphylococcus Aureus 10%
• Monoamine Oxidase Inhibitors 10%
• Once-daily Dosing 10%
• Oral Bioavailability 10%
• Oral Formulation 10%
• Oral Step-down Therapy 10%
• Oxazolidinone 10%
• Pharmacokinetics 100%
• Pharmacokinetics-pharmacodynamics (PK-PD) 10%
• Selective Serotonin Reuptake Inhibitors 10%
• Skin Infection 100%
• Skin Structure Infections 40%
• Spectrum of Activity 10%
• Tedizolid 100%
• Thrombocytopenia 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Antibiotic Agent 20%
• Antibiotics 10%
• Bioavailability 10%
• Clinical Pharmacokinetics 10%
• Coagulase Negative Staphylococcus 10%
• Drug Screening 100%
• Infection 40%
• Infectious Agent 10%
• Linezolid 40%
• Methicillin-Resistant Staphylococcus Aureus 10%
• Monoamine Oxidase Inhibitor 10%
• Oxazolidinone Derivative 10%
• Pharmacodynamics 10%
• Pharmacokinetics 100%
• Reuptake Inhibitor 10%
• Serotonin 10%
• Skin Infection 100%
• Tedizolid 100%
• Thrombocytopenia 10%